Kornitzer Capital Management Inc. KS Acquires 31,330 Shares of Personalis (NASDAQ:PSNL)

Kornitzer Capital Management Inc. KS increased its holdings in Personalis (NASDAQ:PSNL) by 12.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 279,960 shares of the company’s stock after buying an additional 31,330 shares during the period. Kornitzer Capital Management Inc. KS’s holdings in Personalis were worth $4,108,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. SG Americas Securities LLC bought a new position in Personalis in the second quarter worth approximately $228,000. Wellington Shields & Co. LLC bought a new position in Personalis in the second quarter worth approximately $1,765,000. Board of Trustees of The Leland Stanford Junior University bought a new position in Personalis in the second quarter worth approximately $38,749,000. Janus Henderson Group PLC bought a new position in Personalis in the second quarter worth approximately $13,554,000. Finally, Farallon Capital Management LLC bought a new position in Personalis in the second quarter worth approximately $5,021,000. 50.35% of the stock is owned by institutional investors.

Shares of PSNL stock traded up $0.29 during trading hours on Friday, reaching $10.46. 185,500 shares of the company’s stock were exchanged, compared to its average volume of 355,310. The business’s 50 day moving average price is $12.46. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.15. Personalis has a fifty-two week low of $9.65 and a fifty-two week high of $31.88.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.58). The company had revenue of $15.80 million for the quarter, compared to analysts’ expectations of $14.92 million. Personalis’s quarterly revenue was up 79.5% on a year-over-year basis. On average, equities analysts forecast that Personalis will post -0.92 earnings per share for the current year.

A number of equities analysts recently commented on the stock. Zacks Investment Research raised shares of Personalis from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research note on Wednesday, October 23rd. Oppenheimer assumed coverage on shares of Personalis in a research note on Monday, July 15th. They issued an “outperform” rating and a $29.00 price objective for the company. Morgan Stanley assumed coverage on shares of Personalis in a research note on Monday, July 15th. They issued an “overweight” rating and a $28.00 price objective for the company. CIBC assumed coverage on shares of Personalis in a research note on Monday, July 15th. They issued an “outperform” rating and a $29.00 price objective for the company. Finally, Cowen assumed coverage on shares of Personalis in a research note on Monday, July 15th. They issued an “outperform” rating for the company. Six analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus target price of $24.20.

Personalis Company Profile

Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics.

Featured Story: How Do You Calculate Return on Investment (ROI)?

Want to see what other hedge funds are holding PSNL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Personalis (NASDAQ:PSNL).

Institutional Ownership by Quarter for Personalis (NASDAQ:PSNL)

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.